PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circ Res. Author manuscript; available in PMC 2013 September 28.
Published in final edited form as:
PMCID: PMC3500606
NIHMSID: NIHMS411786

Novel Biological Functions of HDL Cholesterol

Chieko Mineo, Ph.D.1 and Philip W. Shaul, M.D.1

Abstract

In addition to its role in reverse cholesterol transport, high density lipoprotein (HDL) cholesterol has direct action on numerous cell types that influence cardiovascular and metabolic health. Cellular responses to HDL entail both its capacity to invoke cholesterol efflux that causes signal initiation via scavenger receptor class B, type I, and plasma membrane receptor activation by HDL cargo molecules. In endothelial cells and their progenitors, HDL attenuates apoptosis and stimulates proliferation and migration. HDL also has diverse anti-inflammatory actions in both endothelial cells and leukocytes. In vascular smooth muscle, HDL tempers pro-inflammatory, pro-migratory and degradative processes, and through actions on endothelium and platelets HDL is anti-thrombotic. There are additional actions of HDL of potential cardiovascular consequence that are indirect, including the capacities to promote pancreatic β-cell insulin secretion, to protect pancreatic β-cells from apoptosis, and to enhance glucose uptake by skeletal muscle myocytes. Furthermore, HDL decreases white adipose tissue mass, it increases energy expenditure, and it promotes the production of the adipose-derived cytokine adiponectin that has its own vascular protective properties. Many of these numerous actions of HDL have been observed not only in cell culture and in animal models, but also in human studies, and assessments of these functions are now being applied to patient populations to better elucidate which actions of HDL may contribute to its cardioprotective potential and how they can be quantified and targeted. Further work on the many mechanisms of HDL action promises to reveal new prophylactic and therapeutic strategies to optimize both cardiovascular and metabolic health.

Keywords: endothelium, high density lipoprotein cholesterol, nitric oxide synthase, scavenger receptor class B, type I

Introduction

Studies of the relationship between circulating concentrations of high density lipoprotein (HDL) cholesterol and atherosclerosis and cardiovascular events have suggested that disease risk is inversely related to HDL level1, 2, and that the association is independent of low density lipoprotein (LDL) cholesterol3, 4. Even in patients treated aggressively with statins to decrease circulating LDL levels to less than 70 mg/dl, HDL may continue to be inversely related to the risk of major cardiovascular events5. However, recent genetic analyses of a relatively common single nucleotide polymorphism (SNP) in the endothelial lipase gene and other SNPs associated with HDL cholesterol suggest that genetic mechanisms that raise plasma HDL do not decrease the risk of myocardial infarction6. In contrast, an earlier study of SNPs in the cholesteryl ester transfer protein (CETP) that impact HDL levels indicated that SNPs associated with an increase in HDL corresponded with a lower risk of future myocardial infarction7. Certain earlier clinical trials with agents that increase HDL showed that elevations in the lipoprotein can decrease the incidence of cardiovascular events 8-10. However, in a recent study the addition of extended-release niacin to simvastatin treatment to raise low levels of HDL did not impact residual cardiovascular disease risk11. In addition, although potential off-target activities of the intervention likely cloud the interpretation of its findings, the ILLUMINATE trial testing the impact of the CETP inhibitor torcetrapib on clinical outcome showed an increase in cardiovascular events and in total mortality despite elevations in HDL cholesterol5. Considering these cumulative observations and the outcomes of numerous other investigations that have interrogated either the level of circulating HDL cholesterol as a disease risk marker, genetic mechanisms that influence HDL level and disease incidence, or the impact of an intervention to raise HDL on clinical outcome, it remains uncertain whether HDL cholesterol directly impacts atherosclerosis and the risk of cardiovascular events. From a mechanistic perspective, HDL classically functions in reverse cholesterol transport (RCT), removing cholesterol from peripheral tissues and cells such as macrophages and delivering it to the liver and to steroidogenic organs by binding of the major HDL apolipoprotein, apolipoprotein A-I (apoA-I), to the high affinity HDL receptor scavenger receptor, class B, type I (SR-BI) 12, 13. In mouse models of atherosclerosis both apoA-I and SR-BI provide atheroprotection 14, 15, and the provision of apoA-I or HDL also attenuates neointima formation after artery injury in the context of experimental hypercholesterolemia16, 17. The potential protective nature of HDL has been primarily attributed to its role in RCT18. However, the mechanisms by which HDL may impact cardiovascular health and disease remain complex and not fully understood 19-23, and it has become quite apparent that alternative mechanisms of action of HDL must be considered.

Our understanding of how HDL potentially modifies cardiovascular disease risk or outcome has expanded well beyond its participation in RCT with the discovery that HDL has direct actions on endothelial cells and other cell types that influence vascular health and disease. This review will highlight advances in this aspect of HDL biology by summarizing findings from experimentation in cell culture and in animal models, and from observational and interventional studies in humans. Direct actions of HDL on cell types of relevance to vascular health and disease will be reviewed first, followed by functions of HDL that may indirectly influence events in the vascular wall. In particular, the regulation of endothelial cell apoptosis, proliferation and migration by HDL, and HDL anti-inflammatory actions in both endothelial cells and leukocytes will be discussed. HDL modulation of vascular smooth muscle and platelet function will also be considered. Since nitric oxide (NO) derived from endothelial nitric oxide synthase (eNOS) has both autocrine and paracrine influence on numerous vascular cell types, the capacity of HDL to modify eNOS subcellular localization, enzymatic activity and expression will be highlighted. More recently appreciated actions of HDL of relevance to glucose homeostasis and adiposity will also be discussed. Furthermore, the basis for intracellular signaling initiated by HDL will be highlighted, and current knowledge gaps in this realm of HDL biology will be considered.

Regulation of Endothelial Cell Apoptosis, Proliferation and Migration

Endothelial Cell Apoptosis

Endothelial cell apoptosis contributes to the pathogenesis of atherosclerosis and other vascular disorders. An intact endothelial cell monolayer plays a critical role in normal homeostasis in the vascular wall, and apoptosis of endothelial cells can occur upon exposure to circulating factors and inflammatory cells, leading to disruption of endothelial monolayer integrity 24. Multiple proatherogenic factors promote apoptosis in endothelium, and these include oxidized LDL (oxLDL) and tumor necrosis factor-α (TNF-α). OxLDL causes a delayed but sustained increase in intracellular calcium in endothelial cells which results in cell death, and this effect is reversed by HDL and mediated by prevention of the calcium increase. The protection afforded by native HDL is mimicked by purified apoA-I and it requires HDL binding to the cells and new protein synthesis25. TNF-α-induced endothelial cell apoptosis is also inhibited by HDL, and this is associated with attenuated induction of CPP32-like protease (caspase 3), which is a component of all primary apoptotic pathways 26. Growth factor depriviation-related apoptosis of endothelial cells is also suppressed by HDL. This is due to blunting of the mitochondrial pathway of apoptosis, with HDL attenuating the dissipation of mitochondrial potential, oxygen-derived free radical generation, cytochrome c release to the cytoplasm, and caspases 3 and 9 activation. HDL also activates Akt and causes phosphorylation of the Akt target BAD, which favors BAD dissassociation from BCL-XL that is then free to inhibit mitochondria-mediated apoptosis. The HDL- associated lysophospholipids sphingosylphosphorylcholine (SPC) and lysosulfatide (LSF) protect endothelial cells from growth factor deprivation-related apoptosis via mechanisms paralleling those of native HDL27. In addition, the lysophospholipid sphingosine-1-phosphate (S1P) enhances endothelial cell survival with effects comparable to those of native HDL, and these responses are inhibited by knockdown of the S1P receptor EDG-1/S1P1, by pertussis toxin, and by PI3 kinase and Erk pathway antagonists, suggesting that signaling by lysophospholipid components of HDL may be important for the inhibition of apoptosis28. Although the vast majority of evidence for antiapoptotic action of HDL on endothelium comes from cell culture work, in studies of the apoA-I mimetic D-4F in a rat model of diabetes, the mimetic improved vascular reactivity and decreased endothelial cell fragmentation and sloughing29. This finding suggests that the anti-apoptotic actions of HDL may be operative in vivo, but additional in vivo evidence is needed.

The potential role of SR-BI in the modulation of endothelial cell apoptosis has been addressed in one report that involved heterologous expression experiments and studies in SR-BI+/+ versus SR-BI-/- fibroblasts and endothelial cells. This work found that a putative redox motif CXXS residing at amino acids 323 to 326 of SR-BI may induce a novel ligand-independent apoptotic pathway mediated by caspase 8. The pro-apoptotic effects of SR-BI were reversed by HDL and by eNOS, and the authors proposed that under normal conditions the antiapoptotic actions of NO prevail, whereas with low levels of HDL, SR-BI may promote endothelial cell death 30. This work is yet to be replicated, and as such, whether SR-BI actually has the potential to invoke apoptosis or affords protection from apoptosis in endothelial cells is yet to be clarified.

Endothelial Cell Proliferation and Migration

The processes of endothelial cell proliferation and migration are crucial to both neovascularization and to a successful response to vascular injury. An intact endothelial cell monolayer modulates local hemostasis and thrombolysis and provides a nonpermeable barrier protecting vascular smooth muscle (VSM) cells from circulating growth-promoting factors. Disruptions of endothelial cell monolayer integrity, either by gross denudation related to a vascular intervention or gap formation between cells due to disturbed shear stress, place the arterial wall at greater risk for vascular disease. Whereas repeated endothelial removal worsens the severity of vascular lesions31, enhanced reendothelialization blunts lesion formation32, 33. Providing another potential mechanism whereby HDL may afford cardiovascular protection, it was demonstrated in the 1980s that the lipoprotein promotes endothelial cell proliferation34, 35, and that the proliferative response is calcium-dependent36. In 1994 it was further reported that HDL stimulates endothelial cell migration independent of cell proliferation. In those early studies the responses to HDL and basic fibroblast growth factor were additive, and the former response was not sensitive to pertussis toxin or inhibition of phospholipase A2 whereas the latter was sensitive, indicating independent signaling mechanisms37. In contrast, in later studies HDL activation of endothelial cell migration was found to be prevented by pertussis toxin, mediated by the G protein-coupled S1P receptors EDG-1/S1P1 and EDG-3/S1P3, and derived from the S1P-rich and not the remaining fractions of HDL. Dependence on PI3 kinase, p38 MAP kinase and Rho kinase was also observed28. Capillary tube formation stimulated by HDL in vitro is pertussis toxin-sensitive but does not occur through p38 MAP kinase and alternatively requires p42/44 MAP kinase activity residing downstream of Ras38. It has also been observed that HDL stimulates endothelial cell migration in vitro in an NO-independent manner via SR-BI-mediated activation of Rac GTPase. This process does not require HDL cargo molecules, and it is dependent on the activation of Src kinases, PI3-kinase, and p44/42 MAP kinases. Rapid initial stimulation of lamellipodia formation by HDL via SR-BI, Src kinases and Rac also occurs in cultured endothelial cells39. Thus, numerous studies have consistently demonstrated that HDL stimulates endothelial cell proliferation and migration. In contrast, there is inconsistency in the signaling mechanisms that have been implicated in these processes. Recognizing that few experiments have been performed in vivo, these inconsistences may relate to the diversity of endothelial cell types that have been studied in culture and also variance in the experimental conditions employed.

Complementing its actions on differentiated endothelial cells, HDL modifies endothelial progenitor cell (EPC) differentiation and function. Although initially believed that circulating EPC contribute to endothelial repair by differentiating into endothelial cells, it is more likely that EPC facilitate vascular repair and neovascularization by secreting paracrine factors40, 41. Reconstituted HDL (rHDL) induces Akt phosphorylation in human peripheral mononuclear cells and promotes their differentiation into EPC in a PI3 kinase-dependent manner42. Mirroring the mechanisms by which HDL activates endothelial cell migration, the activation of EPC proliferation, migration and tube formation by HDL in culture is SR-BI-, PI3 kinase/Akt-, MAP kinase- and eNOS-dependent43, 44. In a hindlimb ischemia model of neovascularization in mice, rHDL infusion causes an increase in capillary density and an augmentation in blood flow recovery that is eNOS-dependent42. In addition, rHDL causes an increase in the number of EPC detected in the aortic endothelium of apoE-/- mice45. Paralleling these findings, carotid artery reendothelialization following perivascular electric injury is diminished in apoA-I-/- mice, reconstitution of apoA-I expression in apoA-I-/- rescues normal reendothelialization, and reendothelialization is impaired in SR-BI-/- mice39. Moreover, a role for SR-BI in EPC modulation by apoA-I/HDL has been demonstrated; whereas adenoviral-driven hepatic expression of human apoA-I causes an increase in circulating EPC in wild-type mice transplanted with SR-BI+/+ bone marrow, the EPC response is absent in mice transplanted with SR-BI-/- bone marrow. In the former group but not in the latter, adenoviral-driven human apoA-I expression also stimulates EPC incorporation and endothelial regeneration in paratopically-transplanted carotid arteries43. Comparable findings regarding human apoA-I transfer and endothelial regeneration have been obtained in a mouse model of transplant atherosclerosis, in which apoA-I also blunts neointima formation46. Thus, HDL causes enhanced EPC differentiation and function and it also stimulates endothelial cell migration via SR-BI-initiated signaling, and there is evidence that these mechanisms promote endothelial monolayer integrity under a variety of experimental conditions in vivo.

Anti-inflammatory Actions in Endothelium and Leukocytes

HDL has anti-inflammatory actions in both endothelial cells and leukocytes. In endothelial cells the lipoprotein inhibits adhesion molecule expression47, and this is mediated by SR-BI, the SR-BI adaptor protein PDZK1, PI3 kinase and eNOS, and in some studies also by S1P receptors, implicating participation by S1P48. Studies in rabbits have demonstrated that VCAM-1 and ICAM-1 expression in the aortic endothelium are blunted by HDL in vivo49, and that the glycation of apoA-I, which occurs in hyperglycemic individuals with diabetes50, impairs this anti-inflammatory property of apoA-I/HDL51. HDL also directly attenuates the activation of monocytes/macrophages and neutrophils52, 53. In monocytes, both native HDL and apoA-I blunt PMA induction of the integrin CD11b, which promotes adhesion and migration, and they thereby decrease PMA-related enhancement of monocyte-endothelial cell interaction53. HDL also inhibits the binding of T cell microparticles to monocytes and thereby blunts proinflammatory cytokine production54. ApoA-I also attenuates dendritic cell differentiation from monocytes55. In macrophages apoA-I actions via ABCA1 that are mediated by STAT3 attenuate LPS induction of inflammatory cytokines56. In neutrophils native HDL and apoA-I decrease the surface expression of CD11b, and they do so via SR-BI and ABCA1, respectively. In parallel, HDL and apoA-I decrease neutrophil spreading and migration, and neutrophil-platelet interaction52. In an in vivo mouse model of inflammation, apoA-I attenuates endothelial cell-leukocyte adhesion assessed by intravital microscopy, and the infusion of rHDL into human subjects with peripheral vascular disease attenuates neutrophil activation52. Interestingly, whereas mice receiving bone marrow transplantation with ABCA1- and ABCG1-deficient marrow display leukocytosis, the leukocytosis is markedly suppressed in apoA-I transgenic mice, indicating that HDL additionally inhibits the proliferation of hematopoietic stem cells and multipotential progenitor cells57. Therefore, there is both cell culture and in vivo evidence that through diverse actions in a number of cell types, HDL has anti-inflammatory properties. The net effect of these processes on cardiovascular conditions that entail inflammation, however, is poorly understood. How HDL influences infectious processes including hepatitis C virus infection are not covered in this review, but are summarized elsewhere58, 59.

Regulation of Vascular Smooth Muscle Cells

Studies in cell culture indicate that HDL has numerous direct actions on vascular smooth muscle (VSM) cells. One action is to enhance VSM cell prostacyclin production, and this results from the upregulation of cyclooxygenase type 2 expression60. HDL also inhibits VSM cell migration via S1P-mediated processes61, 62. Through its S1P cargo, HDL additionally blunts the expression of monocyte chemoattractant protein-1 (MCP-1) in VSM cells, and this is mediated by SR-BI, the S1P3 receptor for S1P, and an attenuation of reactive oxygen species (ROS) production which regulates MCP-1 production. The influence of HDL on ROS production in VSM is through prevention of the activation of Rac1 and resulting inhibition of NAD(P)H oxidase63. Studies of VSM cells have further revealed that HDL has actions on the extracellular matrix. Mass spectrometry and immunoblotting have demonstrated the presence of alpha1-antitrypsin in HDL, and HDL has antielastase activity which blunts extracellular matrix degradation, cell detachment and apopotosis induced by elastase in human VSM cells. The relative abundance of alpha 1-antitrypsin in HDL is decreased in patients with abdominal aortic aneurysm compared with controls, suggesting that HDL from the aneurysm patients is less capable of inhibiting elastase64. Thus, HDL tempers pro-inflammatory, pro-migratory and degradative processes in VSM cells, and along with actions on endothelial cells and leukocytes, these mechanisms may impact atherosclerosis and other vascular disorders.

Regulation of Platelets

Platelet aggregation is inversely correlated with HDL levels in humans65, suggesting that HDL has antiplatelet actions. The inhibition of platelet aggregation has been observed with both the infusion of rats with apoA-I Milano, which is a naturally-occurring mutant form of apoA-I discovered in a village in Italy, and the administration of rHDL to humans, further supporting the concept that HDL inhibits platelet activation in vivo66-68. Mechanistically, whereas HDL may reduce platelet activation directly68, 69, HDL may also act indirectly on platelet activation via one or more of its effects on endothelial cells. In particular, HDL potentially influences platelet function by downregulating the release of platelet activating factor from endothelial cells70 or by activating eNOS71. In the latter case, the increase in bioavailable NO inhibits the release of Weibel-Palade bodies and thus interferes with the activation of the endothelium required for platelet-endothelial cell interactions and thrombosis72, 73. HDL also downregulates endothelial cell thromboxaneA2 synthesis74, and it upregulates endothelial cell prostacyclin production75, which can decrease platelet aggregation76. Furthermore, endothelial cell expression of tissue factor, which plays a key role in the initiation of coagulation, is attenuated by HDL77. Thus, the potential anti-thrombotic actions of HDL are multiple (see 78for additional details).

Modulation of eNOS

The autocrine and paracrine actions of endothelium-derived NO influence vascular cells in numerous ways. Since HDL activation of eNOS and resulting eNOS-dependent processes is becoming a potentially important means of assessing the function of the lipoprotein in the clinical setting (see below), the modulation of eNOS by HDL will be reviewed in considerable detail.

Impact on eNOS Localization

In endothelial cells eNOS is targeted to plasma membrane caveolae, which are a subset of lipid rafts, by both N-terminal myristoylation and palmitoylation79, 80. Caveolae are enriched in cholesterol, glycosphingolipids, sphingomyelin and lipid-anchored membrane proteins, they compartmentalize a variety of signal transduction molecules, and their function is highly dependent on their cholesterol content 81. Cell culture experiments have revealed that oxLDL causes depletion of caveolae cholesterol in endothelial cells via the scavenger receptor CD36, leading to ineffective eNOS targeting to caveolae and an attenuated capacity to activate the enzyme 82, 83. Comparable findings have been obtained in vivo in studies of eNOS localization and function in apoE-/- versus apoE-/-; CD36-/- mice84. In the cell culture paradigm, whereas oxLDL alone disrupts normal eNOS subcellular targeting and function, the addition of HDL to the medium containing oxLDL prevents eNOS displacement from caveolae, and it restores acetylcholine-induced stimulation of the enzyme. The normalization afforded by HDL is due to a prevention of the fall in caveolae sterol content caused by OxLDL, and this is mediated by an SR-BI-dependent provision of cholesterol esters from HDL to the caveolae membrane83. In additional studies, the apoA-I mimetics L4F and D-4F protected endothelial cell function by preventing LDL from uncoupling eNOS activity to favor superoxide anion production over NO production85-87. These processes involving the diminution of the adverse impacts of LDL on the endothelium may explain at least a portion of the antiatherogenic potential of HDL.

Stimulation of eNOS Enzymatic Activity

In addition to normalizing the subcellular localization of the enzyme when the lipid environment within caveolae/lipid rafts is overtly perturbed, HDL is a potent agonist of eNOS. Both heterologous expression experiments and studies of endothelium- and NO-dependent relaxation of aortic rings from wild-type versus knockout mice revealed that SR-BI mediates the activation of eNOS by HDL. The functional coupling of SR-BI to eNOS is demonstrable in isolated endothelial cell caveolae, indicating that all of the molecular machinery required for HDL-induced eNOS stimulation is associated with caveolae71.

In both human and animals studies apoA-I is the apolipoprotein principally responsible for the atheroprotective features of HDL 88. In cultured endothelial cells potential apoA-I-eNOS interaction and perinuclear colocalization have been reported89. However, eNOS enzyme activation has not been observed with lipid-free apoA-I, and corroborating evidence of this interaction is lacking. In isolated endothelial cell plasma membranes anti-apoA-I antibody blocks eNOS activation by HDL, whereas anti-apoA-II antibody causes enhanced eNOS stimulation by HDL. Thus, apoA-I is necessary but not sufficient for eNOS stimulation, and apoA-II may negatively influence eNOS activation by yet-to-be-determined mechanisms71. The impact of apoA-II on HDL modulation of eNOS or resulting processes has not yet been investigated in vivo.

eNOS activity is regulated by complex signal transduction pathways which include the activation of kinases that alter the phosphorylation state of the enzyme. Akt kinase activates eNOS by directly phosphorylating the enzyme at Ser1179 (in bovine eNOS, eNOS-Ser1177 in humans, and eNOS-Ser1176 in mice). Akt itself is phosphorylated and activated by phosphoinositide 3-kinase (PI3 kinase), which in turn is activated by a tyrosine kinase (TK), and both receptor TK and nonreceptor TK participate in eNOS activation by various agonists. In contrast to eNOS-Ser1179, the phosphorylation of eNOS-Thr497 (in bovine eNOS, eNOS-Thr495 in humans) attenuates enzyme activity under certain conditions. eNOS is also modulated by MAP kinases, and unlike Akt, the effect of MAP kinases on eNOS activity can be either positive or negative. Additionally, there is a critical role for calcium-calmodulin binding to eNOS in the regulation of enzyme activity 21. Paralleling this typical mode of agonist activation, the stimulation of the enzyme by HDL entails its phosphorylation at Ser1179 via Akt, and this is mediated by Src family kinases and PI3 kinase. Enzyme activation also requires Src- and PI3 kinase-dependent activation of Erk1/2 MAP kinases90. Paralleling these findings in cell culture, there is increased Akt and Erk1/2 phosphorylation in the aortas of apoA-I transgenic mice and decreased abundance of the phosphorylated proteins in the aortas of apoA-I-/- mice91. It has further been shown using calcium chelation and other approaches that changes in intracellular calcium homeostasis in endothelial cells are required for NO formation in response to HDL92-94.

Role of HDL-associated Molecules and HDL Modifications

A number of studies have indicated that lysophospholipids associated with HDL participate in eNOS activation. For example, native HDL and the potential HDL cargos SPC, S1P, and LSF cause parallel eNOS-dependent relaxation of precontracted aortic rings from mice, and 50-60% of the response to native HDL is lost in rings from mice lacking the lysophospholipid receptor S1P3, which mediates responses to S1P and LSF95. Studies in cell culture have shown that the receptor for SPC in endothelial cells is GPR496, but loss-of-function studies of HDL actions in the absence of GPR4 have not yet been pursued. However, the intravenous administration of HDL stimulates myocardial perfusion in vivo equivalently in wild-type and S1P3-/- mice but not in eNOS-/- mice97. As such, the role of eNOS in HDL-induced vascular responses remains clear whereas the involvement of lysophospholipids as physiologic HDL-associated eNOS agonists may vary between endothelium from different vascular sources.

Prompted by recent findings of attenuated endothelial actions of HDL isolated from patients with coronary artery disease or acute coronary syndrome versus HDL from healthy controls (see below), it has been discovered that malondialdehyde (MDA) associated with HDL can impact the ability of the lipoprotein to activate eNOS. It was found that MDA content is elevated in HDL from coronary disease patients compared with HDL from healthy subjects, that there is a parallel diminution in the capacity of the HDL from the former group to activate eNOS, and that the addition of MDA to HDL from healthy individuals blunts endothelial NO production. The antagonistic action of MDA was determined to be mediated by lectin-type oxidized LDL receptor 1 (LOX-1) activation of PKCβII, which inhibits Akt-activating phosphorylation (Akt-Ser473) and eNOS-activating phosphorylation at Ser1177 (in human eNOS). Since MDA formation is decreased by HDL-associated paraoxonase 1 (PON1)98, PON1 activity was evaluated and it was found to be markedly decreased in HDL from coronary disease patients. Furthermore, PON1 inactivation in HDL from healthy subjects results in greater PKCβII activation in cultured endothelial cells, decreased activating eNOS-Ser1177 phosphorylation and increased inactivating eNOS-Thr495 phosphorylation, resulting in attenuated NO production. Moreover, HDL from Pon1-/- mice fails to stimulate endothelial cell NO production, and the supplementation of Pon1-/- HDL with purified PON1 restores this function99. These collective observations indicate that HDL-associated MDA and PON1 may have major impact on endothelial function, and the latter is consistent with the reported inverse relationship between PON1 activity and cardiovascular disease development100.

In addition to potentially important influences of HDL-associated molecules, oxidative modification of HDL alters its capacity to activate eNOS. Myeloperoxidase-mediated modifications of apoA-I were first recognized to impair HDL-mediated cholesterol efflux from macrophages101, and serum myeloperoxidase levels predict the risk of coronary artery disease and are independently associated with endothelial dysfunction102, 103. These observations prompted studies of the impact of HDL oxidation on the ability of the lipoprotein to stimulate eNOS. The exposure of HDL from healthy subjects to myeloperoxidase-derived oxidants that were either nitrating or chlorinating oxidant species caused complete prevention of eNOS activation104. Therefore, the characteristics of HDL that influence its ability to stimulate eNOS enzymatic activity are multiple.

Impact on eNOS Protein Abundance

In addition to the regulation of NO production by signaling events that modulate eNOS enzymatic activity, important control of eNOS involves changes in the abundance of the enzyme. In cultured human endothelial cells eNOS protein expression is increased 3-fold by HDL exposure for 24h, and the increase in eNOS protein is not associated with a rise in steady-state mRNA levels. Alternatively, it is related to a comparable 3-fold increase in the half-life of the protein, which is mediated by PI3 kinase/Akt and MAP kinases, indicating that the same signaling mechanisms that underlie the acute activation of eNOS by HDL are operative in upregulating the abundance of the enzyme as well105. An upregulation in eNOS protein abundance in response to HDL has also been observed in EPC106. However, whether HDL influences eNOS enzyme abundance in vivo remains unknown.

Modulation of eNOS in Humans

A relationship between HDL and endothelium-dependent vasodilation has been known since 1994 when it was reported that patients with elevated HDL have greater vasodilator and attenuated vasoconstrictor response107. Subsequent studies of flow-mediated vasodilation of the brachial artery revealed that HDL cholesterol is an independent predictor of endothelial function108, 109. In an interventional study of HDL elevation by niacin treatment for 3 months in patients with coronary artery disease and depressed HDL levels, niacin administration and the resulting 25% increase in HDL was associated with a marked improvement in flow-mediated vasodilation110.

The direct, short-term impact of HDL on endothelial function has also been investigated in humans. One study analyzed forearm bloodflow responses in ATP-binding cassette transporter 1 (ABCA1) heterozygotes. Compared to controls, ABCA-1 heterozygotes (6 men and 3 women) had HDL levels which were decreased by 60%, and their blood flow responses to endothelium-dependent vasodilators were blunted in spite of them having normal endothelium-independent responses. Following a 4h infusion of apoA-I/phosphatidylcholine disks, HDL levels in the ABCA1 heterozygotes increased 3-fold and endothelium-dependent vasomotor responses were normalized111. In addition, endothelial function is enhanced in hypercholesterolemic men with normal HDL levels shortly after the administration of apoA-I/phosphatidylcholine particles112. These observations indicate that HDL may be a positive modulator of endothelial NO generation in humans.

Indirect Vascular Actions of HDL

Modulation of Glucose Homeostasis

In addition to its direct actions on cells that govern vascular health and disease, HDL may favorably influence glucose homeostasis and thereby has potentially novel functions that indirectly promote vascular health. ApoA-I/HDL stimulates glucose uptake by skeletal muscle myocytes via increasing AMP-activated protein kinase (AMPK) activity113, it also promotes glycogen synthesis by skeletal muscle myocytes114, and via SR-BI it stimulates glucose uptake by adipocytes114. HDL also promotes insulin secretion by pancreatic β-cells. The latter process requires ABCA1 when lipid-free apoA-I is the stimulus and ABCG1 when recombinant HDL is the stimulus, and with either lipid-free apoA-I or recombinant HDL, pancreatic β-cell SR-BI is required115. Mice with pancreatic β-cell-specific deletion of ABCA1 display glucose intolerance, elegantly demonstrating that these mechanisms are operative in vivo116. Furthermore, whereas VLDL and LDL particles attenuate insulin mRNA levels and β-cell proliferation and cause β-cell apoptosis, HDL antagonizes the propapoptotic signaling by VLDL and LDL in an Akt-dependent manner117, 118. The impact of HDL on glucose homeostasis has also been demonstrated in individuals with type 2 diabetes, with rHDL administration resulting in a lowering of plasma glucose, increases in insulin levels and increased AMPK activity in skeletal muscle119.

Modulation of Adipose

Mouse models have shown that in addition to influencing glucose homeostasis, apoA-I and HDL potentially combat obesity, with the overexpression of apoA-I or the administration of the apoA-I mimetic D-4F decreasing white adipose mass and insulin resistance and increasing energy expenditure in mice placed on high fat diet. Brown adipose tissue was found to be another potential target tissue of apoA-I and HDL action since the overexpression of apoA-I increased uncoupling protein (UCP)1 mRNA abundance in brown adipose in vivo, and parallel findings were made in brown adipocytes in culture120. In ob/ob mice the apoA-I mimetic L-4F lowers adiposity and inflammation and causes an improvement in glucose tolerance121. In addition, apoA-I gene transfer in mice causes an increase in plasma concentrations of the adipokine adiponectin and an increase in adiponectin expression in abdominal fat, and HDL treatment of cultured adipocytes promotes adiponectin expression in a PI3 kinase-dependent manner. Thus, HDL influences the production of an adipose-derived cytokine that itself affords vascular protection122. Furthermore, in patients with type 2 diabetes, the administration of rHDL inhibits fasting-induced lipolysis and oxidation, suggesting additional impact of HDL on lipid homeostasis123. Interestingly, there is also both in vitro and in vivo evidence that adipocytes, which are a potentially large source of free cholesterol, support the transfer of cholesterol to HDL via ABCA1 and SR-BI, indicating potential reciprocal modes of regulation between the lipoprotein and adipose124.

Molecular Basis of HDL Signaling

As outlined above, HDL induces a variety of signaling events which underlie numerous actions of the lipoprotein in target cells125, 126. The molecular basis of HDL signaling that occurs independent of cargo molecules has been investigated by interrogation of the proximal mechanisms in HDL activation of eNOS. In cultured endothelial cells, short-term exposure to HDL or methyl-β-cyclodextrin causes eNOS stimulation of similar magnitude, whereas cholesterol-loaded methyl-β-cyclodextrin does not. Cholesterol-free Lp2A-I particles comprised of lipid-free recombinant apoA-I and phosphatidylcholine also activate eNOS, whereas cholesterol containing Lp2A-I particles do not. In addition, phosphatidylcholine-loaded HDL causes greater eNOS stimulation than native HDL, and blocking antibody to SR-BI, which retards cholesterol efflux, prevents eNOS activation. Furthermore, in a reconstitution system in COS-M6 cells wild-type SR-BI mediates eNOS activation by both HDL and small unilamellar vesicles, whereas the SR-BI mutant AVI, which is incapable of efflux to small unilamellar vesicles, transmits signal only in response to HDL. Moreover, eNOS activation by both HDL and methyl-β-cyclodextrin is SR-BI-dependent127. Since the capacity of methyl-β-cyclodextrin to invoke cholesterol efflux is not mediated by SR-BI or any other cell surface protein, these cumulative findings in the context of eNOS regulation indicate that signal initiation by HDL requires cholesterol efflux, that the apolipoprotein and phospholipid components of HDL are sufficient to initiate signaling, and that SR-BI may serve as a sensor of cholesterol movement in the plasma membrane.

The participation of cholesterol efflux in HDL action has also been evaluated in nonendothelial cells and in processes besides eNOS regulation. In monocytes, HDL and methyl-β-cyclodextrin cause equal antagonism of CD11b expression, which contributes to HDL attenuation of monocyte-endothelial cell adhesion, whereas cholesterol-laden methyl-β-cyclodextrin has no effect53. In pancreatic β-cells, insulin secretion in response to discoidal apoA-I recombinant HDL is absent following ABCG1 knockdown115, and paralleling the actions of native HDL on β-cells, there is an initiation of insulin secretion within 10 min of treatment with methyl-β-cyclodextrin, even in the absence of other insulin secretagogues128. Thus, cholesterol efflux may be mechanistically involved in a variety of the actions of HDL in diverse target cells.

The features of SR-BI required for signal initiation have also been interrogated. Using SR-BII, which is a splice variant of SR-BI, and mutant and chimeric class B scavenger receptors, it was determined that the C-terminal cytoplasmic PDZ-interacting domain and the C-terminal transmembrane domain of SR-BI are both required for HDL signaling. In addition, in studies employing a photoactivated derivative of cholesterol, direct binding of cholesterol to the C-terminal transmembrane domain was demonstrated127. Thus, key domains of SR-BI uniquely mediating HDL signaling have been initially identified.

Assessments of HDL Function

Over the past 10 years, the recognition that variance in plasma HDL cholesterol concentration may not be associated with differences in cardiovascular disease risk, and that HDL has potentially important cardiovascular protective functions besides its participation in RCT has prompted comparisons of HDL function in different patient populations. In studies evaluating the capacity of HDL to blunt LDL-induced monocyte chemotaxis in a human artery coculture system, it was found that whereas the lipoprotein isolated from control subjects effectively inhibited chemotaxis, HDL from coronary heart disease patients with either normal or even elevated circulating HDL levels lacked this function129. In investigations of the ability of HDL to reverse the inhibition of aortic ring endothelium-dependent relaxation by oxLDL, HDL isolated from subjects with type 1 or type 2 diabetes or abdominal obesity had far less effect than HDL prepared from healthy control subjects130-132. It has also been observed that whereas HDL from healthy controls stimulates endothelial NO production, EPC-mediated repair and endothelium-dependent vasodilation, these actions are impaired in HDL obtained from patients with type 2 diabetes104. The endothelial actions of HDL have been further interrogated in a recent investigation of lipoprotein isolated from patients with stable coronary artery disease or acute coronary syndrome versus healthy individuals. The HDL from controls caused an increase in bioavailable NO in endothelial cells and resulting promotion of endothelial repair and an attenuation of NF-kB activation and VCAM-1 expression, thereby preventing endothelial cell-monocyte adhesion; in contrast, the HDL from coronary disease patients lacked these properties, and this was found to be related to elevated MDA content that was further attributed to a decrease in HDL-associated PON1 activity (further details are provided above)133. Thus, valuable information about HDL functions beyond those involved in the processes in RCT in different patient populations is emerging.

Along with learning more about the functions of HDL in various patient groups, changes in HDL action in response to therapies targeting the lipoprotein have also been observed. In addition to raising HDL cholesterol plasma levels in patients with type 2 diabetes, extended-release niacin therapy was found to cause improvements in the endothelial protective functions of the lipoprotein104. Treatment with the CETP inhibitor torcetrapib resulted in a modest increase in the capacity of HDL to invoke net cholesterol efflux from foam cells134, mirroring the enhanced efflux capacity of HDL from individuals with CETP deficiency135. Through continuing accumulation of observations of this type, assessments of HDL function both comparing different patient populations and assessing changes with therapeutic intervention will enhance our understanding of the novel actions of the lipoprotein.

Current Knowledge Gaps

Our present understanding of the cellular targets of HDL action and the mechanisms by which the lipoprotein initiates intracellular signaling are summarized in Figure 1 and Figure 2, respectively. The current knowledge gaps in this realm of HDL biology are multiple. First, we do not know which proximal processes invoked by HDL in various target cells are shared amongst the different cell types and functional responses, and which are unique. Cholesterol efflux by HDL is important in eNOS activation in endothelial cells and it likely participates in anti-inflammatory processes in HDL-exposed monocytes and the capacity of HDL to promote pancreatic β-cell insulin secretion. However, whether cholesterol efflux is a uniform mechanism whereby HDL initiates intracellular signaling in other HDL target cells warrants elucidation. Second, although we have gained a reasonable understanding of the initial intracellular signaling events, such as kinase cascade activation, that may be prompted by HDL in various cell types, we have a meager understanding of the genes whose expression is modified by HDL in its various target cells. Third, we do not know to what extent each of the many functions of HDL that we have discussed in this review impacts cardiovascular and/or metabolic health. Fourth, we do not know if assays of HDL action on endothelial cells, or leukocytes or vascular smooth muscle cells for example, will increase our ability to assign cardiovascular disease risk, or if they will enhance our understanding of the outcomes of future trials testing HDL-targeted therapies. Finally, remembering that HDL particles are comprised of approximately 100 different proteins and a large variety of lipid species, and that HDL subclasses differ in their numerous physical and chemical properties136, we currently have a modest understanding of how most of these features influence the functions of the lipoprotein and therefore the cellular responses to the lipoprotein. What we do now know, however, is that the influence of HDL on both cardiovascular and metabolic health likely goes well beyond its classical role in global cholesterol homeostasis. With a greater understanding of the many mechanisms of action of HDL, a variety of new therapeutic opportunities will potentially be revealed.

Figure 1
Cell Targets of HDL Action
Figure 2
Mechanisms of HDL Signal Initiation

Acknowledgments

Sources of Funding

This work was supported by NIH Grant No. HL058888, the Crystal Charity Ball Center for Pediatric Critical Care Research, the Children’s Medical Center Foundation, and the Lowe Foundation.

Non-standard Abbreviations and Acronyms

apoA-I
apolipoprotein A-I
eNOS
endothelial NO synthase
EPC
endothelial progenitor cell
HDL
high density lipoprotein
LDL
low density lipoprotein
LOX-1
lectin-type oxidized LDL receptor 1
LSF
lysosulfatide
MCP-1
monocyte chemoattractant protein-1
MDA
malondialdehyde
PON-1
paraoxonase-1
RCT
reverse cholesterol transport
rHDL
reconstituted HDL
ROS
reactive oxygen species
S1P
sphingosine-1-phosphate
SPC
sphingosylphosphorylcholine
TNF-α
tumor necrosis factor α
VSM
vascular smooth muscle

Footnotes

Disclosures

None.

References

1. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res. 1999;40:187–201. [PubMed]
2. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989;321:1311–6. [PubMed]
3. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol. 2001;88:9N–13N. [PubMed]
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14. [PubMed]
5. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10. [PubMed]
6. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de FU, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de BA, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de WF, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–80. [PMC free article] [PubMed]
7. Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2:26–33. [PMC free article] [PubMed]
8. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92. [PubMed]
9. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8. [PubMed]
10. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L–22L. [PubMed]
11. Boden WE, Probstfield JL, Anderson T, Chaitman BR, svignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. [PubMed]
12. Krieger M. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523–58. [PubMed]
13. Connelly MA, Williams DL. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol. 2004;15:287–95. [PubMed]
14. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002;90:270–6. [PubMed]
15. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447–52. [PubMed]
16. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935–41. [PubMed]
17. De Geest B, Zhao Z, Collen D, Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 1997;96:4349–56. [PubMed]
18. Rosenson RS, Brewer HB, Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19. [PubMed]
19. Krieger M. The “best” of cholesterols, the “worst” of cholesterols: a tale of two receptors. Proc Natl Acad Sci U S A. 1998;95:4077–80. [PubMed]
20. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36. [PubMed]
21. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749–74. [PubMed]
22. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927–38. [PubMed]
23. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 1994;89(Suppl 1):87–102. [PubMed]
24. Dimmeler S, Haendeler J, Zeiher AM. Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol. 2002;13:531–6. [PubMed]
25. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol. 1997;17:2158–66. [PubMed]
26. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun. 2000;272:872–6. [PubMed]
27. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480–5. [PubMed]
28. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23:1283–8. [PubMed]
29. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, Abraham NG. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation. 2005;111:3126–34. [PubMed]
30. Li XA, Guo L, Dressman JL, Asmis R, Smart EJ. A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. J Biol Chem. 2005;280:19087–96. [PubMed]
31. Niimi Y, Azuma H, Hirakawa K. Repeated endothelial removal augments intimal thickening and attenuates EDRF release. Am J Physiol. 1994;266:H1348–H1356. [PubMed]
32. Rossig L, Dimmeler S, Zeiher AM. Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol. 2001;96:11–22. [PubMed]
33. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003;93:e17–e24. [PubMed]
34. Tauber JP, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J Clin Invest. 1980;66:696–708. [PMC free article] [PubMed]
35. Tauber JP, Cheng J, Massoglia S, Gospodarowicz D. High density lipoproteins and the growth of vascular endothelial cells in serum-free medium. In Vitro. 1981;17:519–30. [PubMed]
36. Tamagaki T, Sawada S, Imamura H, Tada Y, Yamasaki S, Toratani A, Sato T, Komatsu S, Akamatsu N, Yamagami M, Kobayashi K, Kato K, Yamamoto K, Shirai K, Yamada K, Higaki T, Nakagawa K, Tsuji H, Nakagawa M. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis. 1996;123:73–82. [PubMed]
37. Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ Res. 1994;74:1149–56. [PubMed]
38. Miura S, Fujino M, Matsuo Y, Kawamura A, Tanigawa H, Nishikawa H, Saku K. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:802–8. [PubMed]
39. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ, Shaul PW. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006;98:63–72. [PubMed]
40. Hagensen MK, Vanhoutte PM, Bentzon JF. Arterial endothelial cells: still the craftsmen of regenerated endothelium. Cardiovasc Res. 2012;95:281–9. [PubMed]
41. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624–37. [PMC free article] [PubMed]
42. Sumi M, Sata M, Miura S, Rye KA, Toya N, Kanaoka Y, Yanaga K, Ohki T, Saku K, Nagai R. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:813–8. [PubMed]
43. Feng Y, Van Eck M, Van Craeyveld E, Jacobs F, Carlier V, Van Linthout S, Erdel M, Tjwa M, De Geest B. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood. 2009;113:755–64. [PubMed]
44. Zhang Q, Yin H, Liu P, Zhang H, She M. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. Exp Biol Med (Maywood) 2010;235:1082–92. [PubMed]
45. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006;26:1144–9. [PubMed]
46. Feng Y, Jacobs F, Van CE, Brunaud C, Snoeys J, Tjwa M, Van LS, De GB. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28:278–83. [PubMed]
47. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–94. [PubMed]
48. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im DS, Sato K, Murakami M, Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem. 2006;281:37457–67. [PubMed]
49. Patel S, Di Bartolo BA, Nakhla S, Heather AK, Mitchell TW, Jessup W, Celermajer DS, Barter PJ, Rye KA. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 2010;212:392–7. [PubMed]
50. Curtiss LK, Witztum JL. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes. 1985;34:452–61. [PubMed]
51. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, Bonnet DJ, Curtiss LK, Barter PJ, Rye KA. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2010;30:766–72. [PMC free article] [PubMed]
52. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, Sviridov D, Chin-Dusting JP. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1333–41. [PubMed]
53. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–7. [PubMed]
54. Carpintero R, Gruaz L, Brandt KJ, Scanu A, Faille D, Combes V, Grau GE, Burger D. HDL interfere with the binding of T cell microparticles to human monocytes to inhibit proinflammatory cytokine production. PLoS ONE. 2010;5:e11869. [PMC free article] [PubMed]
55. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, Paik SG, Kim YS, Yang Y, Lim JS. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun. 2005;338:1126–36. [PubMed]
56. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem. 2009;284:32336–43. [PubMed]
57. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328:1689–93. [PMC free article] [PubMed]
58. Dao TV, Dreux M, Cosset FL. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev Mol Med. 2011;13:e13. [PubMed]
59. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22:9–15. [PMC free article] [PubMed]
60. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2) Arterioscler Thromb Vasc Biol. 1997;17:3481–8. [PubMed]
61. Tamama K, Tomura H, Sato K, Malchinkhuu E, Damirin A, Kimura T, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis. 2005;178:19–23. [PubMed]
62. Damirin A, Tomura H, Komachi M, Liu JP, Mogi C, Tobo M, Wang JQ, Kimura T, Kuwabara A, Yamazaki Y, Ohta H, Im DS, Sato K, Okajima F. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol. 2007;292:H2513–H2522. [PubMed]
63. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der GM, Nofer JR. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol. 2008;28:1542–8. [PMC free article] [PubMed]
64. Ortiz-Munoz G, Houard X, Martin-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J. 2009;23:3129–39. [PubMed]
65. Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol. 1999;84:1011–7. [PubMed]
66. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, Khan S, Mehta JL. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol. 1999;19:378–83. [PubMed]
67. Pajkrt D, Lerch PG, van der PT, Levi M, Illi M, Doran JE, Arnet B, van den EA, ten Cate JW, van Deventer SJ. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost. 1997;77:303–7. [PubMed]
68. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095–104. [PubMed]
69. Lerch PG, Spycher MO, Doran JE. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost. 1998;80:316–20. [PubMed]
70. Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal. 1996;13:73–88. [PubMed]
71. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–7. [PubMed]
72. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O’Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;115:139–50. [PMC free article] [PubMed]
73. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, Wakefield TW, Lammle B, Massberg S, Wagner DD. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400–7. [PubMed]
74. Oravec S, Demuth K, Myara I, Hornych A. The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion. Thromb Res. 1998;92:65–71. [PubMed]
75. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982;257:6653–5. [PubMed]
76. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114:784–94. [PMC free article] [PubMed]
77. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergeres G, Rusconi S, Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res. 2004;94:918–25. [PubMed]
78. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352–64. [PubMed]
79. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, Michel T. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem. 1996;271:6518–22. [PubMed]
80. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A. 1996;93:6448–53. [PubMed]
81. Chang WJ, Rothberg KG, Kamen BA, Anderson RG. Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. J Cell Biol. 1992;118:63–9. [PMC free article] [PubMed]
82. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–9. [PubMed]
83. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278–83. [PubMed]
84. Kincer JF, Uittenbogaard A, Dressman J, Guerin TM, Febbraio M, Guo L, Smart EJ. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction. J Biol Chem. 2002;277:23525–33. [PubMed]
85. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA., Jr L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003;107:2337–41. [PubMed]
86. Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard KA., Jr L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation. 2003;107:1520–4. [PubMed]
87. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA., Jr Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res. 2005;97:1190–7. [PMC free article] [PubMed]
88. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92:42J–9J. [PubMed]
89. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci U S A. 2004;101:6999–7004. [PubMed]
90. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142–9. [PubMed]
91. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation. 2005;111:2805–11. [PubMed]
92. Honda HM, Wakamatsu BK, Goldhaber JI, Berliner JA, Navab M, Weiss JN. High-density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells. Atherosclerosis. 1999;143:299–306. [PubMed]
93. Nofer JR, van der GM, Tolle M, Wolinska I, von Wnuck LK, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–81. [PMC free article] [PubMed]
94. Li XA, Titlow WB, Jackson BA, Giltiay N, Nikolova-Karakashian M, Uittenbogaard A, Smart EJ. High Density Lipoprotein Binding to Scavenger Receptor, Class B, Type I Activates Endothelial Nitric-oxide Synthase in a Ceramide-dependent Manner. J Biol Chem. 2002;277:11058–63. [PubMed]
95. Nofer JR, van der GM, Tolle M, Wolinska I, von Wnuck LK, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–81. [PMC free article] [PubMed]
96. Kim KS, Ren J, Jiang Y, Ebrahem Q, Tipps R, Cristina K, Xiao YJ, Qiao J, Taylor KL, Lum H, nand-Apte B, Xu Y. GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine. FASEB J. 2005;19:819–21. [PubMed]
97. Levkau B, Hermann S, Theilmeier G, van der GM, Chun J, Schober O, Schafers M. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation. 2004;110:3355–9. [PubMed]
98. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–90. [PMC free article] [PubMed]
99. Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des. 2010;16:1480–93. [PubMed]
100. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, van der GY. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol. 2009;54:1238–45. [PubMed]
101. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–41. [PMC free article] [PubMed]
102. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF, Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–9. [PMC free article] [PubMed]
103. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–42. [PubMed]
104. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121:110–22. [PubMed]
105. Ramet ME, Ramet M, Lu Q, Nickerson M, Savolainen MJ, Malzone A, Karas RH. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol. 2003;41:2288–97. [PubMed]
106. Noor R, Shuaib U, Wang CX, Todd K, Ghani U, Schwindt B, Shuaib A. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis. 2007;192:92–9. [PubMed]
107. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994;89:2525–32. [PubMed]
108. Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 2000;73:231–6. [PubMed]
109. Kuvin JT, Patel AR, Sidhu M, Rand WM, Sliney KA, Pandian NG, Karas RH. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol. 2003;92:275–9. [PubMed]
110. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144:165–72. [PubMed]
111. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–8. [PubMed]
112. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–402. [PubMed]
113. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia. 2007;50:1960–8. [PubMed]
114. Zhang Q, Zhang Y, Feng H, Guo R, Jin L, Wan R, Wang L, Chen C, Li S. High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS ONE. 2011;6:e23556. [PMC free article] [PubMed]
115. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642–8. [PubMed]
116. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340–7. [PubMed]
117. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278:18368–75. [PubMed]
118. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, von EA. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009;150:4521–30. [PubMed]
119. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Court, Forbes JM, Yap FY, Kaye DM, van HG, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103–11. [PubMed]
120. Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, Feng GS, Chen Y. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med. 2011;15:763–72. [PubMed]
121. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res. 2008;49:1658–69. [PubMed]
122. Van LS, Foryst-Ludwig A, Spillmann F, Peng J, Feng Y, Meloni M, Van CE, Kintscher U, Schultheiss HP, De GB, Tschope C. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis. 2010;210:438–44. [PubMed]
123. Drew BG, Carey AL, Natoli AK, Formosa MF, Vizi D, Reddy-Luthmoodoo M, Weir JM, Barlow CK, van HG, Meikle PJ, Duffy SJ, Kingwell BA. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. J Lipid Res. 2011;52:572–81. [PubMed]
124. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, Rothblat GH, Reilly MP. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 2010;23:121, 1347–55. [PMC free article] [PubMed]
125. Grewal T, de D I, Kirchhoff MF, Tebar F, Heeren J, Rinninger F, Enrich C. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem. 2003;278:16478–81. [PubMed]
126. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1–16. [PubMed]
127. Assanasen C, Mineo C, Seetharam D, Yuhanna IS, Marcel YL, Connelly MA, Williams DL, Llera-Moya M, Shaul PW, Silver DL. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest. 2005;115:969–77. [PMC free article] [PubMed]
128. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328–38. [PubMed]
129. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6. [PubMed]
130. Persegol L, Verges B, Foissac M, Gambert P, Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006;49:1380–6. [PubMed]
131. Persegol L, Foissac M, Lagrost L, Athias A, Gambert P, Verges B, Duvillard L. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2007;50:2384–7. [PubMed]
132. Persegol L, Verges B, Gambert P, Duvillard L. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res. 2007;48:1396–401. [PubMed]
133. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von EA, Fogelman AM, Luscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693–708. [PMC free article] [PubMed]
134. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8. [PubMed]
135. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006;116:1435–42. [PMC free article] [PubMed]
136. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol. 2011;22:176–85. [PubMed]